ACS Applied Materials & Interfaces,
Год журнала:
2025,
Номер
unknown
Опубликована: Июнь 3, 2025
Immune-suppressive
tumor-associated
macrophages
(TAMs)
that
infiltrate
the
tumor
microenvironment
(TME),
along
with
presence
of
blood-brain
barrier
(BBB),
influence
effectiveness
immunotherapy
for
glioblastoma.
In
this
study,
we
report
use
difluoromethylornithine
(DFMO),
aPD-L1,
and
Indocyanine
Green
(ICG)
in
combination
target
TAMs
their
repolarization.
DFMO
repolarizes
by
inhibiting
expression
aconitate
decarboxylase
1
(ACOD1),
while
aPD-L1
blocks
PD-1/PD-L1
immune
checkpoint
on
TAMs,
achieving
efficient
phenotypic
switching
enhancing
phagocytic
activity
against
glioblastoma
(GBM).
When
combined
photothermal
agent
ICG,
effect
induces
immunogenic
cell
death
further
strengthens
repolarization
TAMs.
This
increases
conversion
efficiency
reverses
suppression
at
site,
transforms
anti-inflammatory
"cold"
into
a
pro-inflammatory
"hot"
tumor.
approach
showed
better
therapeutic
effects
an
orthotopic
glioma
model
mice,
our
treatment
+
N-aP@ICG
(nanovesicles
containing
ICG),
increasing
179%
compared
to
other
treatments
glioma.
summary,
propose
innovative
glioma,
which
effectively
penetrates
barrier,
targets
M2-TAMs,
enhances
response,
inhibits
proliferation
Vaccines,
Год журнала:
2025,
Номер
13(4), С. 337 - 337
Опубликована: Март 21, 2025
Dendritic
cells
(DCs)
act
as
a
bridge
between
innate
and
adaptive
immunity
by
presenting
antigens
to
effector
immune
have
shown
broad
application
potential
in
tumor
immunotherapy.
However,
the
clinical
translation
of
DC
vaccines
encounters
significant
challenges,
such
immunosuppressive
microenvironment
(TME)
sub-optimal
function
vaccine
efficacy
vivo.
In
this
review,
our
investigation
has
uncovered
latest
developments
their
cancer
immunotherapy,
with
special
emphasis
on
integration
nanotechnology.
Several
types
nanomaterials,
including
protein
cage
nanoparticles
(NPs),
biomimetic
NPs,
targeted
multifunctional
been
developed
enhance
antigen
presentation
ability
DCs
stimulatory
effects
T
cells.
addition,
we
also
summarized
synergistic
anti-cancer
checkpoint
inhibitors,
chemotherapy,
radiotherapy.
recent
advances
nanotechnology
made
it
possible
develop
novel
biomarkers
that
can
capacity
stimulate
These
not
only
improve
accuracy
precision
design
but
provide
new
insights
into
understanding
mechanisms
DC-mediated
response.
Despite
challenges
pertaining
technical
complexities
individual
adaptation
production
vaccines,
personalized
immunotherapy
based
is
expected
become
an
important
part
treatment
rapid
biotechnology
immunology.
This
review
provides
perspectives
solutions
for
optimal
therapy.
Abstract
Glioblastoma
represents
a
highly
aggressive
form
of
malignant
tumor
within
the
central
nervous
system.
Although
chemotherapy
remains
primary
therapeutic
strategy,
its
efficacy
is
often
limited.
To
overcome
limitations
associated
with
chemotherapeutic
agents,
such
as
high
toxicity
and
non‐specific
adverse
effects,
novel
nanoparticle
system
comprising
cRGD‐modified
glutathione
(GSH)‐responsive
polymers,
PEG‐ss‐Dox
apatinib
(AP)
(PDOX‐AP/cRGD‐NPs)
developed.
PDOX‐AP/cRGD‐NPs
show
effective
penetration
blood‐brain
barrier
(BBB),
facilitate
targeted
delivery
to
brain
tumors,
exhibit
controlled
drug
release.
more
effect
in
reducing
viability
GL‐261,
U87‐MG,
LN‐229
cells,
inhibiting
clonogenicity,
suppressing
anti‐apoptotic
protein
expression
than
PDOX/cRGD‐NPs
or
AP/cRGD‐NPs.
Additionally,
substantially
increase
uptake,
BBB
penetration,
apoptosis
rates,
proportion
cells
G2
phase.
In
vivo
experiments
further
reveal
that
cRGD‐directed
nanoparticles
superior
accumulation
glioma
regions
compared
their
non‐cRGD‐modified
counterparts.
interim,
demonstrate
significant
both
ectopic
orthotopic
growth
GL‐261
gliomas,
well
thereby
markedly
extending
median
survival
duration.
This
study
introduces
promising
co‐delivery
for
combination
chemotherapy.
Journal of Controlled Release,
Год журнала:
2025,
Номер
unknown, С. 113682 - 113682
Опубликована: Апрель 1, 2025
Following
successful
design
of
polymer
enhanced
rituximab-epirubicin
(EPI)
conjugates
targeted
to
non-Hodgkin
lymphoma
(Zhang
et
al.
2017),
we
developed
U6244-051
that
consists
anti-PD-L1
antibody
(αPD-L1)
and
semitelechelic
N-(2-hydroxypropyl)methacrylamide
(HPMA)
copolymer-epirubicin
(ST-P-EPI);
the
latter
is
attached
αPD-L1
via
Cu-free
azide/alkyne
cycloaddition.
This
new
polymer-enhanced
antibody-drug
conjugate
(pADC)
not
only
exhibits
a
high
drug-to-antibody
ratio
(DAR
~
30-40)
but
also
integrates
immune
checkpoint
blockade
with
long-lasting
immunogenic
anticancer
chemotherapy,
providing
an
innovative
chemo-immuno
combination
modality.
The
biological
properties
were
evaluated
using
ID8-Luc
murine
ovarian
cancer
cells
in
vitro
vivo.
In
vitro,
treatment
induced
immunomodulatory
changes,
including
upregulation
calreticulin,
PD-L1,
MHC
I,
suggesting
tumor
cell
visibility
system.
vivo
efficacy
was
assessed
syngeneic
model
(C57BL/6
J
mice
inoculated
5
×
106
cells/mouse).
resulted
100
%
survival
at
day
100,
despite
initiation
advanced
disease
stage.
Treatment
modulated
microenvironment
by
reducing
immunosuppressive
populations
(TAMs
MDSCs)
enhancing
T
recruitment
activation.
A
decrease
PD-L1
expression
increased
I
correlated
immune-mediated
clearance.
Additionally,
reduced
Treg
levels
CD8+
activation
contributed
more
effective
antitumor
response.
Repeated
dosing
amplified
effects,
leading
durable
immunity.
These
results
highlight
as
next-generation
pADC
translational
potential,
offering
on-target,
off-tumor
toxicity.
Macromolecular Chemistry and Physics,
Год журнала:
2025,
Номер
unknown
Опубликована: Май 2, 2025
Abstract
This
study
presents
a
simple
strategy
to
develop
tumor‐acidity
responsive
core‐crosslinked
micellar
nanoassembly
capable
of
delivering
multiple
drugs
combat
drug
resistance.
Paclitaxel
(PTX)
nanocrystals
are
prepared
using
D‐α‐tocopherol
polyethylene
glycol
1000
succinate
(TPGS)
as
an
emulsifier
and
cross‐linked
with
poly(β‐cyclodextrin)
(PCD)
form
the
core.
An
acid‐labile
prodrug,
poly(ethylene
glycol)‐doxorubicin
(mPEG‐DOX),
is
utilized
shell,
forming
core‐shell
(CSNA)
via
supramolecular
interactions.
The
CSNA
demonstrated
high
stability
in
aqueous
serum
environments,
triggered
shell‐detachment
response
tumor
acidity.
nanomedicine
exhibited
superior
inhibition
drug‐resistant
cancer
cell
line
MCF‐7/ADR
compared
DOX
or
PTX
alone,
offering
potential
overcome
resistance
chemotherapy.
ACS Applied Materials & Interfaces,
Год журнала:
2025,
Номер
unknown
Опубликована: Май 6, 2025
Effective
eradication
of
cancer
cells
while
minimizing
damage
to
normal
tissues
remains
a
significant
challenge
in
clinical
oncology.
Herein,
multifunctional
nanoplatform
(DFD-MIP)
was
developed
through
sequential
fabrication
doxorubicin
(DOX)-loaded
inner
layer
and
P32
epitope-imprinted
outer
on
Fe3O4
nanoparticles
(NPs),
using
dopamine
as
both
functional
monomer
cross-linker.
To
assess
therapeutic
superiority
DFD-MIP,
comprehensive
vitro
vivo
studies
were
conducted.
Results
demonstrated
that
the
served
an
artificial
antibody
for
overexpressed
tumor
cell
recognition
"gatekeeper"
prevent
drug
leakage
during
circulation,
thereby
reducing
systemic
toxicity.
Upon
cellular
internalization,
acidic
microenvironment
triggered
degradation
polydopamine
(PDA)-based
layers,
enabling
pH-responsive
DOX
release
directly
within
cells.
Synergistically,
under
808
nm
near-infrared
irradiation,
combined
photothermal
conversion
capabilities
NPs
PDA
residues
generated
enhanced
hyperthermia.
This
chemo-photothermal
combination
therapy
achieved
superior
suppression
localized
activation
thermal
ablation
residual
DFD-MIP
integrated
multiple
desirable
features
including
simplified
composition,
active
targeting
capability,
excellent
biocompatibility,
prolonged
retention,
release.
platform
significantly
improves
chemotherapeutic
bioavailability
off-target
effects,
providing
prototype
development
targeted
delivery
systems.
ACS Biomaterials Science & Engineering,
Год журнала:
2025,
Номер
unknown
Опубликована: Май 8, 2025
Prostate
cancer
is
the
second
most
common
among
men
globally.
In
this
study,
we
developed
a
prostate-cancer-targeted
gold
nanoparticle-based
photothermal
and
photodynamic
complex
(GNR-ICG-FA@PSMA)
to
enhance
targeting
efficiency
of
prostate
cells
simultaneously
deliver
therapy
(PTT)
(PDT).
For
in
vitro
tests,
ROS
assays,
annexin
V/PI
staining,
MTT
assays
were
conducted.
vivo
fluorescence
photoacoustic
imaging
systems
used
track
distribution
nanoparticles
animal
models.
Tumor
tissues
analyzed
post-treatment
using
Triphenyl
tetrazolium
chloride
(TTC)
Hematoxylin
Eosin
(HE)
Immunohistochemistry
(IHC)
staining.
The
results
showed
that
GNR-ICG
with
laser
irradiation
produced
high
levels
ROS,
highest
rate
apoptosis,
lowest
cell
viability.
tail-injected
GNR-ICG-FA@PSMA
reached
tumor
within
9
h.
During
irradiation,
GNRs
increased
temperature
(<50
°C),
inducing
necrosis,
while
ICGs
generated
leading
apoptosis.
demonstrated
folic
acid
(FA)
PSMA
antibodies
improved
cancer-specific
targeting.
contributed
effects,
respectively.
This
study
confirms
potential
for
targeted
cancer.